Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION study

Quiz Summary

0 of 3 Questions completed

Questions:

You have already completed the quiz before. Hence you can not start it again.

Quiz is loading…

You must sign in or sign up to start the quiz.

You must first complete the following:

Results

Quiz complete. Results are being recorded.

Results

0 of 3 Questions answered correctly

Your time:

You have reached 0 of 0 point(s), (0)

Current
Review
Answered
Correct
Incorrect

Question 1 of 3

1. Question
A 38-year-old female patient with a 3-year history of chronic spontaneous urticaria (CSU) presents to the pharmacy. She has been on high-dose second-generation H1 antihistamines with inadequate symptom control. She has never received anti-IgE therapy. Her baseline IgE levels are low. She inquires about new treatment options beyond antihistamines and omalizumab.

Based on the INCEPTION study findings, what is the most appropriate counseling point regarding tezepelumab for this patient?
- Tezepelumab provides rapid symptom relief within 4 weeks similar to omalizumab.
- Tezepelumab may offer a delayed but sustained improvement in CSU symptoms, especially in anti-IgE-naive patients with low baseline IgE.
- Tezepelumab is not recommended due to a high incidence of adverse effects compared to placebo.
- Tezepelumab has demonstrated superior efficacy to omalizumab in all CSU patients regardless of prior therapy.
Correct

Incorrect
Question 2 of 3

2. Question
A 45-year-old male with chronic spontaneous urticaria refractory to high-dose antihistamines is considering biologic therapy. He has no prior exposure to anti-IgE agents. He asks about the differences between omalizumab and newer agents like tezepelumab and dupilumab.

Which statement best reflects the current evidence-based understanding of these therapies for CSU?
- Omalizumab remains the standard of care with rapid onset, while tezepelumab may provide a delayed, sustained effect; dupilumab shows efficacy by week 24 targeting IL-4/13 pathways.
- Tezepelumab has demonstrated superior rapid symptom control compared to omalizumab and dupilumab in phase 3 trials.
- Dupilumab is ineffective in CSU and should not be considered as an alternative to omalizumab or tezepelumab.
- All three agents have identical mechanisms of action and onset of effect.
Correct

Incorrect
Question 3 of 3

3. Question
A 50-year-old female with CSU refractory to antihistamines is initiated on tezepelumab therapy. She is concerned about potential adverse effects and safety monitoring during treatment.

What information should the pharmacist provide regarding the safety profile of tezepelumab based on the INCEPTION study?
- Tezepelumab has a safety profile comparable to placebo with no significant increase in adverse events.
- Tezepelumab is associated with a high risk of severe allergic reactions and requires hospitalization monitoring.
- Routine laboratory monitoring is mandatory due to frequent hematologic toxicities.
- Tezepelumab use is contraindicated in patients with a history of asthma or atopic conditions.
Correct

Incorrect

Quiz Summary

Information

Results

Results

Categories

1. Question

2. Question

3. Question